

August 25th, 2022

ARCALIS, Inc.

**Notice concerning Discussions with Meiji Seika Pharma Regarding the Production
and Supply of “ARCT-154” for Replicon Vaccine for COVID-19**

ARCALIS, Inc. (Headquarters: Kashiwa, Chiba, Japan; President & CEO: Tomoyuki Fujisawa; hereinafter referred to as "ARCALIS") announced today that ARCALIS has entered into discussions with Meiji Seika Pharma Inc. (Head Office: Chuo-ku, Tokyo; President: Daikichiro Kobayashi; hereinafter referred to as "Meiji Seika Pharma") regarding the production and supply in Japan of replicon vaccine ARCT-154, a replicon vaccine (next-generation mRNA vaccine) that is potentially useful against mutant strains such as Omicron strain, developed by Arcturus Therapeutics Inc. (Head Office: San Diego, U.S.A.; President & CEO: Joseph E. Payne)

Production is planned to take place at the Minamisoma Plant in Fukushima Prefecture, which is currently under construction by the Company.

Details will be disclosed promptly after the conclusion of the agreement.

Contact

ARCALIS Eri Yokota

<https://corp.arcalis.co.jp/#contact>